An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Trial Profile

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate057
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 18 Oct 2017 Results of a subgroup analyses in patients with baseline liver metastases from two phase III trials (CheckMate 017 and 05; n=193) presented at the 18th World Conference on Lung Cancer
    • 12 Oct 2017 Results of pooled analysis of CheckMate 017 and CheckMate 057 assessing two year efficacy outcomes published in the Journal of Clinical Oncology.
    • 15 Sep 2017 Results of pooled analysis of this trial and three other trials (70036762, 700220443, 700225594) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top